+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 50Years +
All Genders
ID06346600

Long-Term Observational Follow-Up of SKG0106 in Patients with Neovascular Wet Age-Related Macular Degeneration

Led by Skyline Therapeutics · Updated on 2026-09-01

83

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a long-term follow-up study to evaluate SKG0106 in patients with neovascular wet age-related macular degeneration nAMD. This observational study involves participants who have previously completed parent clinical trials involving SKG0106 injections. The aim is to monitor safety and efficacy outcomes up to five years after the initial study drug injection. No new investigational treatments will be given during this study. Instead, participants from three groups, each previously exposed to different SKG0106 dose levels, will undergo safety and efficacy assessments over the follow-up period. These assessments include tracking adverse events and changes in vision and retinal thickness without additional drug administration. Participants will undergo evaluations including visual acuity tests, retinal imaging to measure macular thickness, and patient-reported outcome questionnaires at scheduled visits up to five years post injection. The main focus is on identifying any ocular or systemic adverse events, changes in visual function, and patient quality of life over this extended monitoring period. The study duration allows for thorough long-term safety and efficacy observation.

CONDITIONS

Brief Title

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

Research Team

E

Eddy Anglade, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here